BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $345 from $315 and keeps a Neutral rating on the shares. The firm is increasing its target multiples for McKesson (MCK) and Cencora following peer Cardinal Health’s (CAH) strong quarter highlighting the robust demand environment and positive broad-based industry utilization trends, the analyst tells investors. Cencora will report fiscal Q4 earnings before market open on November 5, the analyst noted.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- COR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cencora price target raised to $340 from $334 at Mizuho
- Cencora price target raised to $380 from $350 at UBS
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says